LENIOLISIB | LENIOLISIB | ATC L03AX22
ANTINEOPLASTIC KINASE INHIBITOR INDICATED FOR THE TREATMENT OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA (PI3K DELTA) SYNDROME (APDS) | ORAL | Tmax 1 HOUR VD 28.5 LITER PPB 94.5 PERCENT HT 10 HOUR SOLUBILITY DECREASING SOLUBILITY OBSERVED WITH INCREASING PH | PHOSPHOINOSITIDE 3-KINASE DELTA (PI3K DELTA) PDB 5O83 (DISCOVERY OF CDZ173 (LENIOLISIB), REPRESENTING A STRUCTURALLY NOVEL CLASS OF PI3K DELTA-SELECTIVE INHIBITORS) LIGAND CODE = 9NQ (link to the list of PDB complexes) Download experimental 3D coordinates of 9NQ with added hydrogens | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform PK3CD UNIPROT O00329 more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |